Actively Recruiting
Evaluation of Ibuzatrelvir Alone and With Remdesivir for Treatment of COVID-19 in Severely Immunocompromised Adults
Led by Pfizer · Updated on 2026-10-14
300
Participants Needed
159
Research Sites
18 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and efficacy of ibuzatrelvir alone and in combination with remdesivir compared to remdesivir alone in treating symptomatic COVID-19 among severely immunocompromised adults. This Phase 3, randomized, double-blind study focuses on participants who are non-hospitalized or have mild-to-moderate COVID-19 at baseline. The trial aims to better understand treatment options for this vulnerable patient group who may face prolonged infections and severe illness progression. Participants are assigned to one of three groups ibuzatrelvir taken orally twice daily plus intravenous remdesivir, ibuzatrelvir plus intravenous placebo, or oral placebo plus intravenous remdesivir. The study uses matching placebos to maintain blinding. Treatment durations and specific dosing schedules are carefully monitored to compare the combination and monotherapy effects over the study period. During approximately 10 study visits over 24 weeks, participants will attend clinic visits for blood tests, nasal swabs collected both in-clinic and at home, and complete questionnaires. Researchers will assess outcomes such as symptom alleviation, viral RNA levels, rates of infection recurrence, hospital visits, and safety events. This comprehensive monitoring helps evaluate the impact of the treatments on COVID-19 symptoms and viral clearance in immunocompromised adults.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here